Skip to main content

OP/Bone

RT @KDAO2011: We are underdiagnosing this!

In pts with persistently low ALP, think hypophoshatasia (HPP); these pts ha

k dao KDAO2011

2 weeks 2 days ago
We are underdiagnosing this! In pts with persistently low ALP, think hypophoshatasia (HPP); these pts have recurrent poor healing fractures, may have CPPD, and have been refractory to standard OP Rx. Dr. A Abelson #ACRReview @rheumnow #ACR20 https://t.co/dVptFkYXR2
RT @KDAO2011: Dr. A Abelson #ACRReview @rheumnow #ACR20
Romosozumab (sclerostin Ab) for OP:
👉can be used after previ

k dao KDAO2011

2 weeks 2 days ago
Dr. A Abelson #ACRReview @rheumnow #ACR20 Romosozumab (sclerostin Ab) for OP: 👉can be used after previous treatmt with PTH analogs 👉can be used in pts with prior radiation exposure 👉not yet approved for men. Some slides on what to choose for OP and when to choose it https://t.co/nAbOmEjx3p
RT @DrBhana: from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reim

Suleman Bhana, MD DrBhana

2 weeks 2 days ago
from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reimbursement for DEXA/Bone Density. @ACRheum has been advocating on Capitol Hill to restore reimbursement. Bad policy harms, but good policy can save lives. #ACRambassador https://t.co/ARo762Vozp
RT @vksandhumd: ARCH study -- n~4100
Romo vs Alendronate x 12 mo
Alendronate 12-24 mo
RRR 38% https://t.co/d0G7x4TqUT

Vaneet K Sandhu, MD vksandhumd

2 weeks 2 days ago
ARCH study -- n~4100 Romo vs Alendronate x 12 mo Alendronate 12-24 mo RRR 38% https://t.co/d0G7x4TqUT
RT @synovialjoints: How do we square up bone loss and new bone formation in AS? Are these coupled? Study from the ASSERT

Dr. Antoni Chan synovialjoints

2 weeks 3 days ago
How do we square up bone loss and new bone formation in AS? Are these coupled? Study from the ASSERT trial showed no relationship between baseline BMD and new syndesmophyte formation in the same vertebra @RheumNow #ACR20 Abstr#1896
RT @RHEUMarampa: Study of Chinese pts on long-term GCs by Dr CC Mok: DEN >> ALN in ⬆spinal BMD & suppressing

sheila RHEUMarampa

2 weeks 4 days ago
Study of Chinese pts on long-term GCs by Dr CC Mok: DEN >> ALN in ⬆spinal BMD & suppressing bone turnover markers after 1yr tx. No sig. diff in AEs among grps. Limits: Open-label,small ss,short tx dur'n, not powered for fractures @RheumNow #ACR20 abs1442 https://t.co/m8mT0hMPN8
RT @KDAO2011: #ACRKnowledgeBowl #acr20 @rheumnow
This % of bone loss is assc with a T-score -1.5 on a DXA

k dao KDAO2011

2 weeks 4 days ago
#ACRKnowledgeBowl #acr20 @rheumnow This % of bone loss is assc with a T-score -1.5 on a DXA
Male Osteoporosis: Dr. Kathryn Dao

Dr. Kathryn Dao reviews abstract #0533 presented at the 2020 ACR annual meeting.

RT @ejdein1: Re Abs#760: Bone erosions in +CCP not predictive of development of IA. You have a pt with no synovitis, but

Eric Dein ejdein1

2 weeks 5 days ago
Re Abs#760: Bone erosions in +CCP not predictive of development of IA. You have a pt with no synovitis, but +CCP, small bone erosion on standing foot xray. Do you treat? #ACR20 @Rheumnow
RT @ejdein1: Dr Hansen at 3S008 on "Bone for the Holidays": individualize the decision for drug holidays - here are the

Eric Dein ejdein1

2 weeks 5 days ago
Dr Hansen at 3S008 on "Bone for the Holidays": individualize the decision for drug holidays - here are the key questions: #acr20 @Rheumnow https://t.co/lMHtYW4OzE
×